ATE264398T1 - Regulierte expression von proteinen in stabil transformierten säugetierzellen - Google Patents

Regulierte expression von proteinen in stabil transformierten säugetierzellen

Info

Publication number
ATE264398T1
ATE264398T1 AT96940158T AT96940158T ATE264398T1 AT E264398 T1 ATE264398 T1 AT E264398T1 AT 96940158 T AT96940158 T AT 96940158T AT 96940158 T AT96940158 T AT 96940158T AT E264398 T1 ATE264398 T1 AT E264398T1
Authority
AT
Austria
Prior art keywords
pct
gene therapy
parvovirus
expression
date jun
Prior art date
Application number
AT96940158T
Other languages
English (en)
Inventor
Markus Peter Wilhelm Einerhand
Domenico Valerio
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE264398T1 publication Critical patent/ATE264398T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96940158T 1995-12-01 1996-11-29 Regulierte expression von proteinen in stabil transformierten säugetierzellen ATE264398T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203307 1995-12-01
PCT/NL1996/000472 WO1997020943A1 (en) 1995-12-01 1996-11-29 Regulated protein expression in stably transfected mammalian cells

Publications (1)

Publication Number Publication Date
ATE264398T1 true ATE264398T1 (de) 2004-04-15

Family

ID=8220893

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940158T ATE264398T1 (de) 1995-12-01 1996-11-29 Regulierte expression von proteinen in stabil transformierten säugetierzellen

Country Status (9)

Country Link
US (1) US6140103A (de)
EP (1) EP0870044B1 (de)
JP (1) JP3881382B2 (de)
AT (1) ATE264398T1 (de)
AU (1) AU7710996A (de)
DE (1) DE69632201T2 (de)
DK (1) DK0870044T3 (de)
ES (1) ES2219700T3 (de)
WO (1) WO1997020943A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
AU1576501A (en) * 1999-10-28 2001-05-08 Research Development Foundation Methods to enhance and confine gene expression in cancer therapy
MX359371B (es) * 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
EP2543734A1 (de) * 2011-07-07 2013-01-09 Deutsches Krebsforschungszentrum Adenoparvovirus-Chimäre mit verbessertem Onkolysepotential
EP3456822A1 (de) * 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Induzierbare aav rep gene
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
GB201901571D0 (en) * 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
ES2216005T3 (es) * 1993-11-09 2004-10-16 Targeted Genetics Corporation Produccion de titulos elevados de vectores de aav recombinantes.
US5851796A (en) * 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products

Also Published As

Publication number Publication date
US6140103A (en) 2000-10-31
DK0870044T3 (da) 2004-08-02
EP0870044A1 (de) 1998-10-14
EP0870044B1 (de) 2004-04-14
DE69632201D1 (de) 2004-05-19
WO1997020943A1 (en) 1997-06-12
JP3881382B2 (ja) 2007-02-14
ES2219700T3 (es) 2004-12-01
AU7710996A (en) 1997-06-27
DE69632201T2 (de) 2005-04-21
JP2000501934A (ja) 2000-02-22

Similar Documents

Publication Publication Date Title
US11674128B2 (en) Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
Humme et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold
Delecluse et al. A first-generation packaging cell line for Epstein–Barr virus-derived vectors
Oligino et al. Vector systems for gene transfer to joints.
Alexander et al. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results
PT728214E (pt) Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
DE69824859D1 (de) Methoden zur erhöhung der effizienz rekombinanter aav produkte
DE69535703D1 (de) Aav-vermittelte überbringung von dna in zellen des nervensystems
KR960010864A (ko) 동물 세포의 형질 감염을 위한 재조합 dna 바이러스 벡터
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
AU7599500A (en) Novel gl50 molecules and uses therefor
CA2294598A1 (en) Transcriptional activators with graded transactivation potential
AUPN477695A0 (en) Gene therapy
DE69839584D1 (de) Verfahren zur erhöhung der leistungsfähigkeit der rekombinanten aav produktion
Alaee et al. Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair
DK0988391T3 (da) Rekombinante adenovirusvektorer der omfatter en splejsningssekvens
DE69739211D1 (de) Verpackungszellinien in der Verwendung zur Erleichterung der Entwicklung hocheffizienter adenoviraler Vektoren
ATE264398T1 (de) Regulierte expression von proteinen in stabil transformierten säugetierzellen
Fenjves Approaches to gene transfer in keratinocytes
Gonçalves et al. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells
Wang et al. Shortened nuclear matrix attachment regions are sufficient for replication and maintenance of episomes in mammalian cells
Fehse et al. Highly‐efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin
Cao et al. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy
Wonderling et al. The Rep68 protein of adeno-associated virus type 2 stimulates expression of the platelet-derived growth factor B c-sis proto-oncogene
Wright Gene therapy for the eye

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0870044

Country of ref document: EP